Preliminary efficacy and safety of Relmacabtagene autoleucel (Carteyva) in adults with relapsed/refractory follicular lymphoma in China: A phase I/II clinical trial

被引：3

作者：

Ying, Zhitao ^{[1
]}

Zou, Dehui ^{[2
,3
]}

Yang, Haiyan ^{[4
]}

Wu, Jianqiu ^{[5
]}

Guo, Ye ^{[6
]}

Li, Wenyu ^{[7
]}

Liu, Hui ^{[8
]}

Wang, Chris ^{[9
]}

Ma, Laura ^{[9
]}

Yang, Su ^{[9
]}

Zhou, Zisong ^{[9
]}

Qin, Yun ^{[9
]}

Song, Yuqin ^{[1
]}

Zhu, Jun ^{[1
]}

机构：

[1] Peking Univ Canc Hosp & Inst, Dept Lymphoma, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, 52 Fucheng Rd, Beijing 100142, Peoples R China

[2] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol, Dept Lymphoma & Myeloma, Tianjin, Peoples R China

[3] Chinese Acad Med Sci & Peking Union Med Coll, Blood Dis Hosp, State Key Lab Expt Hematol, Tianjin, Peoples R China

[4] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Chinese Acad Sci, Canc Hosp,Inst Basic Med & Canc IBMC,Dept Lymphom, Hangzhou, Zhejiang, Peoples R China

[5] Nanjing Med Univ, Jiangsu Canc Hosp, Jiangsu Inst Canc Res, Jiangsu Red Cross Canc Ctr,Dept Med Oncol, Nanjing, Peoples R China

[6] Tongji Univ, Shanghai Dongfang Hosp, Dept Oncol, Shanghai, Peoples R China

[7] Guangdong Acad Sci, Guangdong Prov Peoples Hosp, Dept Lymphoma, Guangzhou, Guangdong, Peoples R China

[8] Beijing Hosp, Dept Hematol, Beijing, Peoples R China

[9] JW Therapeut Shanghai Co Ltd, Shanghai, Peoples R China

来源：

AMERICAN JOURNAL OF HEMATOLOGY | 2022年 / 97卷 / 12期

关键词：

D O I：

10.1002/ajh.26711

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：E436 / E438

页数：3

共 50 条

[31] A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma
Maly, Joseph J.
Christian, Beth A.
Zhu, Xiaohua
Wei, Lai
Sexton, Jennifer L.
Jaglowski, Samantha M.
Devine, Steven M.
Fehniger, Todd A.
Wagner-Johnston, Nina D.
Phelps, Mitch A.
Bartlett, Nancy L.
Blum, Kristie A.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (06) : 347 - 353
[32] Efficacy and safety of relmacabtagene autoleucel, an anti-CD19 chimeric antigen receptor T cell, in relapsed/refractory B-cell non-Hodgkin's lymphoma: 2-year results of a phase 1 trial
Ying, Zhitao
Xie, Yan
Zheng, Wen
Liu, Weiping
Lin, Ningjing
Tu, Meifeng
Wang, Xiaopei
Ping, Lingyan
Deng, Lijuan
Zhang, Chen
Wu, Meng
Feng, Feier
Du, Tingting
Tang, Yongjing
Su, Fang
Guo, Ziyu
Li, James
Song, Yuqin
Zhu, Jun
BONE MARROW TRANSPLANTATION, 2023, 58 (03) : 288 - 294
[33] Efficacy and safety of relmacabtagene autoleucel, an anti-CD19 chimeric antigen receptor T cell, in relapsed/refractory B-cell non-Hodgkin’s lymphoma: 2-year results of a phase 1 trial
Zhitao Ying
Yan Xie
Wen Zheng
Weiping Liu
Ningjing Lin
Meifeng Tu
Xiaopei Wang
Lingyan Ping
Lijuan Deng
Chen Zhang
Meng Wu
Feier Feng
Tingting Du
Yongjing Tang
Fang Su
Ziyu Guo
James Li
Yuqin Song
Jun Zhu
Bone Marrow Transplantation, 2023, 58 : 288 - 294
[34] Phase I/II Clinical Trial of Temsirolimus and Lenalidomide in Patients with Relapsed and Refractory Lymphomas
Major, Ajay
Kline, Justin
Karrison, Theodore G.
Fishkin, Paul A. S.
Kimball, Amy S.
Petrich, Adam M.
Nattam, Sreenivasa
Sleckman, Bethany G.
Cohen, Kenneth
van Besien, Koen
Rapoport, Aaron P.
Smith, Sonali M.
BLOOD, 2020, 136
[35] Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas
Major, Ajay
Kline, Justin
Karrison, Theodore G.
Fishkin, Paul A. S.
Kimball, Amy S.
Petrich, Adam M.
Nattam, Sreenivasa
Rao, Krishna
Sleckman, Bethany G.
Cohen, Kenneth
van Besien, Koen
Rapoport, Aaron P.
Smith, Sonali M.
HAEMATOLOGICA, 2022, 107 (07) : 1608 - 1618
[36] Phase I/II study of galiximab, an Anti-CD80 antibody, for relapsed or refractory follicular lymphoma
Czuczman, MS
Thall, A
Witzig, TE
Vose, JM
Younes, A
Emmanouilides, C
Miller, TP
Moore, JO
Leonard, JP
Gordon, LI
Sweetenham, J
Alkuzweny, B
Finucane, DM
Leigh, BR
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (19) : 4390 - 4398
[37] Phase II Trial of Lenalidomide in Patients with Relapsed or Refractory Hodgkin Lymphoma
Kuruvilla, John
Taylor, Diane
Wang, Lisa
Blattler, Chantale
Keating, Armand
Crump, Michael
BLOOD, 2008, 112 (11) : 1049 - 1049
[38] Preliminary Results from a Phase I Trial of Pembrolizumab Plus Vorinostat in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Hodgkin Lymphoma
Herrera, Alex F.
Chen, Lu
Popplewell, Leslie L.
Budde, Lihua E.
Mei, Matthew
Armenian, Saro H.
Darrah, Justin
Nikolaenko, Liana
Chen, Robert W.
Peters, Lacolle
Kennedy, Neena
Rosen, Steven
Forman, Stephen J.
Kwak, Larry W.
BLOOD, 2019, 134
[39] Phase II Trial of Temsirolimus for Relapsed/Refractory Primary CNS Lymphoma
Korfel, Agnieszka
Schlegel, Uwe
Herrlinger, Ulrich
Dreyling, Martin
Schmidt, Christian
von Baumgarten, Luisa
Pezzutto, Antonio
Grobosch, Thomas
Kebir, Sied
Thiel, Eckhard
Martus, Peter
Kiewe, Philipp
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15) : 1757 - +
[40] Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma (CITADEL-203)
Lynch, Ryan C.
Paneesha, Shankara
Avigdor, Abraham
McKinney, Matthew S.
Wahlin, Bjorn E.
Hrom, John S.
Belada, David
Canales, Miguel
Cunningham, David
Devizzi, Liliana
Morley, Nicholas
Zheng, Fred
DeMarini, Douglas J.
Jiang, Wei
Trneny, Marek
BLOOD, 2020, 136

← 1 2 3 4 5 →